New insights into the molecular mechanisms of the fibrinolytic system

Journal of Thrombosis and Haemostasis

Volumn 7, Issue 1, 2009, Pages 4-13

  Rijken, Dingeman C ^a   Lijnen, H R ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Brinolysis; PAI 1; Plasminogen; t PA; TAFI; u PA

Indexed keywords

ALPHA 2 ANTIPLASMIN; ALPHA ENOLASE; FIBRIN; GANGLIOSIDE; HISTONE H2B; PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE; UROKINASE RECEPTOR;

CELL SURFACE; CRYSTAL STRUCTURE; ENDOTHELIUM CELL; FIBRIN CLOT; FIBRINOLYSIS; HUMAN; NONHUMAN; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW;

BLOOD PROTEINS; FIBRIN; FIBRINOLYSIS; HUMANS;

EID: 57749189817     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2008.03220.x     Document Type: Review

References (106)

1. Rijken DC., Wijngaards G, Welbergen J. Immunological characterization of plasminogen activator activities in human tissues and body fluids. J Lab Clin Med 1981; 97: 477-86.
2. Collen D, Lijnen HR. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 1991; 78: 3114-24.
3. Blasi F. Urokinase and urokinase receptor: A paracrine/autocrine system regulating cell migration and invasiveness. Bioessays 1993; 15: 105-11.
4. Booth NA. Fibrinolysis and thrombosis. Baillieres Best Pract Res Clin Haematol 1999; 12: 423-33.
5. Huntington JA, Read RJ, Carrell RW. Structure of a serpin-protease complex shows inhibition by deformation. Nature 2000; 407: 923-6.
6. Forsgren M, Raden B, Israelsson M, Larsson K, Heden LO. Molecular cloning and characterization of a full-length cDNA clone for human plasminogen. FEBS Lett 1987; 213: 254-60.
7. Castellino FJ, Ploplis VA. Structure and function of the plasminogen/ plasmin system. Thromb Haemost 2005; 93: 647-54.
8. Collen D. On the regulation and control of fibrinolysis. Thromb Haemost 1980; 43: 77-89.
9. Rijken DC, Collen D. Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. J Biol Chem 1981; 256: 7035-41.
10. Pennica D, Holmes WE, Kohr WJ, Harkins RN, Vehar GA, Ward CA, Bennett WF, Yelverton E, Seeburg PH, Heyneker HL, Goeddel DV, Collen D. Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli. Nature 1983; 301: 214-21.
11. Rijken DC, Hoylaerts M, Collen D. Fibrinolytic properties of one-chain and two-chain human extrinsic (tissue-type) plasminogen activator. J Biol Chem 1982; 257: 2920-5.
12. Lijnen HR, Collen D. Strategies for the improvement of thrombolytic agents. Thromb Haemost 1991; 66: 88-110.
13. Rijken DC. Plasminogen activators and plasminogen activator inhibitors: biochemical aspects. Baillieres Clin Haematol 1995; 8: 291-312.
14. Bode W, Renatus M. Tissue-type plasminogen activator: Variants and crystal/solution structures demarcate structural determinants of function. Curr Opin Struct Biol 1997; 7: 865-72.
15. Holmes WE, Pennica D, Blaber M, Rey MW, Guenzler WA, Steffens GJ, Heyneker HL. Cloming and expression of the gene for pro-urokinase in Escherichia coli. Nat Biotechnol 1985; 3: 923-9.
16. De Munk GA, Groeneveld E, Rijken DC. Acceleration of the thrombin inactivation of single chain urokinase-type plasminogen activator (pro-urokinase) by thrombomodulin. J Clin Invest 1991; 88: 680-4.
17. Spraggon G, Phillips C, Nowak UK, Ponting CP, Saunders D, Dobson CM, Stuart DI, Jones EY. The crystal structure of the catalytic domain of human urokinase-type plasminogen activator. Structure 1995; 3: 81-91.
18. Ploug M. Structure-function relationships in the interaction between the urokinase-type plasminogen activator and its receptor. Curr Pharm Des 2003; 9: 1499-528.
19. Llinas P, Le Du MH, Gardsvoll H, Dano K, Ploug M, Gilquin B, Stura EA, Ménez A. Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide. EMBO J 2005; 24: 1655-63.
20. Barinka C, Parry G, Callahan J, Shaw DE, Kuo A, Bdeir K, Cines DB, Mazar A, Lubkowski J. Structural basis of interaction between urokinase-type plasminogen activator and its receptor. J Mol Biol 2006; 363: 482-95.
21. Huai Q, Zhou A, Lin L, Mazar AP, Parry GC, Callahan J, Shaw DE, Furie B, Furie BC, Huang M. Crystal structures of two human vitronectin, urokinase and urokinase receptor complexes. Nat Struct Mol Biol 2008; 15: 422-3.
22. Holmes WE, Nelles L, Lijnen HR, Collen D. Primary structure of human alpha 2-antiplasmin, a serine protease inhibitor (serpin). J Biol Chem 1987; 262: 1659-64.
23. Christensen S, Valnickova Z, Thogersen IB, Olsen EH, Enghild JJ. Assignment of a single disulphide bridge in human alpha2-antiplasmin: implications for the structural and functional properties. Biochem J 1997; 323: 847-52.
24. Frank PS, Douglas JT, Locher M, Llinas M, Schaller J. Structural/ functional characterization of the alpha 2-plasmin inhibitor C-terminal peptide. Biochemistry 2003; 42: 1078-85.
25. Wang H, Yu A, Wiman B, Pap S. Identification of amino acids in antiplasmin involved in its noncovalent 'lysine-binding-site'-dependent interaction with plasmin. Eur J Biochem 2003; 270: 2023-9.
26. Law RH, Sofian T, Kan WT, Horvath AJ, Hitchen CR, Langendorf CG, Buckle AM, Whisstock JC, Coughlin PB. X-ray crystal structure of the fibrinolysis inhibitor alpha2-antiplasmin. Blood 2008; 111: 2049-52.
27. Lee KN, Jackson KW, Christiansen VJ, Lee CS, Chun JG, McKee PA. Antiplasmin-cleaving enzyme is a soluble form of fibroblast activation protein. Blood 2006; 107: 1397-404.
28. Christiansen VJ, Jackson KW, Lee KN, McKee PA. The effect of a single nucleotide polymorphism on human alpha 2-antiplasmin activity. Blood 2007; 109: 5286-92.
29. Pannekoek H, Veerman H, Lambers H, Diergaarde P, Verweij CL, van Zonneveld AJ, van Mourik JA. Endothelial plasminogen activator inhibitor (PAI): A new member of the Serpin gene family. EMBO J 1986; 5: 2539-44.
30. Declerck PJ, De Mol M, Alessi MC, Baudner S, Paques EP, Preissner KT, Müller-Berghaus G, Collen D. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J Biol Chem 1988; 263: 15454-61.
31. Nar H, Bauer M, Stassen JM, Lang D, Gils A, Declerck PJ. Plasminogen activator inhibitor 1. Structure of the native serpin, comparison to its other conformers and implications for serpin inactivation. J Mol Biol 2000; 297: 683-95.
32. Hägglöf P, Bergström F, Wilczynska M, Johansson LB, Ny T. The reactive-center loop of active PAI-1 is folded close to the protein core and can be partially inserted. J Mol Biol 2004; 335: 823-32.
33. Gils A, Declerck PJ. The structural basis for the pathophysiological relevance of PAI-1 in cardiovascular diseases and the development of potential PAI-1 inhibitors. Thromb Haemost 2004; 91: 425-37.
34. Eaton DL, Malloy BE, Tsai SP, Henzel W, Drayna D. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. J Biol Chem 1991; 266: 21833-8.
35. Buelens K, Hillmayer K, Compernolle G, Declerck PJ, Gils A. Biochemical importance of glycosylation in thrombin activatable fibrinolysis inhibitor. Circ Res 2008; 102: 295-301.
36. Valnickova Z, Christensen T, Skottrup P, Thogersen IB, Hojrup P, Enghild JJ. Post-translational modifications of human thrombin-activatable fibrinolysis inhibitor (TAFI): Evidence for a large shift in the isoelectric point and reduced solubility upon activation. Biochemistry 2006; 45: 1525-35.
37. Barbosa Pereira PJ, Segura-Martin S, Oliva B, Ferrer-Orta C, Aviles FX, Coll M, Gomis-Rüth FX, Vendrell J. Human procarboxypeptidase B: three-dimensional structure and implications for thrombin-activatable fibrinolysis inhibitor (TAFI). J Mol Biol 2002; 321: 537-47.
38. Marx PF, Brondijk TH, Plug T, Romijn RA, Hemrika W, Meijers JC, Huizinga EG. Crystal structures of TAFI elucidate the inactivation mechanism of activated TAFI; a novel mechanism for enzyme auto-regulation. Blood 2008; 112: 2803-9.
39. Anand K, Pallares I, Valnickova Z, Christensen T, Vendrell J, Wendt KU, Schreuder HA, Enghild JJ, Aviles FX. The crystal structure of TAFI provides the structural basis for its intrinsic activity and the short half-life of TAFIa. J Biol Chem 2008; 283: 29416-23.
40. Sanglas L, Valnickova Z, Arolas JL, Pallares I, Guevara T, Sola M, Kristensen T, Enghild JJ, Aviles FX, Gomis-Ruth FX. Structure of activated thrombin-activatable fibrinolysis inhibitor, a molecular link between coagulation and fibrinolysis. Mol Cell 2008; 31: 598-606.
41. Willemse JL, Heylen E, Hendriks DF. The intrinsic enzymatic activity of procarboxypeptidase U (TAFI) does not significantly influence the fibrinolysis rate: A rebuttal. J Thromb Haemost 2007; 5: 1334-6.
42. Foley JH, Kim P, Nesheim ME. Thrombin-activable fibrinolysis inhibitor zymogen does not play a significant role in the attenuation of fibrinolysis. J Biol Chem 2008; 283: 8863-7.
43. Hoylaerts M, Rijken DC, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem 1982; 257: 2912-9.
44. Thorsen S. The mechanism of plasminogen activation and the variability of the fibrin effector during tissue-type plasminogen activator-mediated fibrinolysis. Ann N Y Acad Sci 1992; 667: 52-63.
45. Medved L, Nieuwenhuizen W. Molecular mechanisms of initiation of fibrinolysis by fibrin. Thromb Haemost 2003; 89: 409-19.
46. Doolittle RF, Pandi L. Binding of synthetic B knobs to fibrinogen changes the character of fibrin and inhibits its ability to activate tissue plasminogen activator and its destruction by plasmin. Biochemistry 2006; 45: 2657-67.
47. Rijken DC, Sakharov DV. Basic principles in thrombolysis: Regulatory role of plasminogen. Thromb Res 2001; 103 (Suppl. 1): S41-9.
48. Sakharov DV, Plow EF, Rijken DC. On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B. J Biol Chem 1997; 272: 14477-82.
49. Weisel JW. Structure of fibrin: Impact on clot stability. J Thromb Haemost 2007; 5 (Suppl. 1): 116-24.
50. Miles LA, Dahlberg CM, Plescia J, Felez J, Kato K, Plow EF. Role of cell-surface lysines in plasminogen binding to cells: Identification of alpha-enolase as a candidate plasminogen receptor. Biochemistry 1991; 30: 1682-91.
51. Hawley SB, Tamura T, Miles LA. Purification, cloning, and characterization of a profibrinolytic plasminogen-binding protein, TIP49a. J Biol Chem 2001; 276: 179-86.
52. Pluskota E, Soloviev DA, Bdeir K, Cines DB, Plow EF. Integrin alphaMbeta2 orchestrates and accelerates plasminogen activation and fibrinolysis by neutrophils. J Biol Chem 2004; 279: 18063-72.
53. Herren T, Burke TA, Das R, Plow EF. Identification of histone H2B as a regulated plasminogen receptor. Biochemistry 2006; 45: 9463-74.
54. Das R, Burke T, Plow EF. Histone H2B as a functionally important plasminogen receptor on macrophages. Blood 2007; 110: 3763-72.
55. Hajjar KA, Nachman RL. Endothelial cell-mediated conversion of Glu-plasminogen to Lys-plasminogen. Further evidence for assembly of the fibrinolytic system on the endothelial cell surface. J Clin Invest 1988; 82: 1769-78.
56. Zhang L, Gong Y, Grella DK, Castellino FJ, Miles LA. Endogenous plasmin converts Glu-plasminogen to Lys-plasminogen on the monocytoid cell surface. J Thromb Haemost 2003; 1: 1264-70.
57. Felez J, Miles LA, Fabregas P, Jardi M, Plow EF, Lijnen RH. Characterization of cellular binding sites and interactive regions within reactants required for enhancement of plasminogen activation by tPA on the surface of leukocytic cells. Thromb Haemost 1996; 76: 577-84.
58. Cesarman-Maus G, Hajjar KA. Molecular mechanisms of fibrinolysis. Br J Haematol 2005; 129: 307-21.
59. Ishii H, Yoshida M, Hiraoka M, Hajjar KA, Tanaka A, Yasukochi Y, Numano F. Recombinant annexin II modulates impaired fibrinolytic activity in vitro and in rat carotid artery. Circ Res 2001; 89: 1240-5.
60. Ling Q, Jacovina AT, Deora A, Febbraio M, Simantov R, Silverstein RL, Hempstead B, Mark WH, Hajjar KA. Annexin II regulates fibrin homeostasis and neoangiogenesis in vivo. J Clin Invest 2004; 113: 38-48.
61. Cesarman-Maus G, Rios-Luna NP, Deora AB, Huang B, Villa R, Cravioto Mdel C, Alarcón-Segovia D, Sánchez-Guerrero J, Hajjar KA. Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome. Blood 2006; 107: 4375-82.
62. Kassam G, Choi KS, Ghuman J, Kang HM, Fitzpatrick SL, Zackson T, Zackson S, Toba M, Shinomiya A, Waisman DM. The role of annexin II tetramer in the activation of plasminogen. J Biol Chem 1998; 273: 4790-9.
63. Waisman DM. Annexin A2 may not play a role as a plasminogen receptor. Br J Haematol 2005; 131: 553-4.
64. Kwon M, MacLeod TJ, Zhang Y, Waisman DM. S100A10, annexin A2, and annexin a2 heterotetramer as candidate plasminogen receptors. Front Biosci 2005; 10: 300-25.
65. Otter M, Kuiper J, van Berkel TJ, Rijken DC. Mechanisms of tissue-type plasminogen activator (tPA) clearance by the liver. Ann N Y Acad Sci 1992; 667: 431-42.
66. Strickland DK, Kounnas MZ, Williams SE, Argraves WS. LDL Receptor-related protein (LRP): A multiligand receptor. Fibrinolysis 1994; 8 (Suppl. 1): 204-15.
67. Noorman F, Braat EA, Rijken DC. Degradation of tissue-type plasminogen activator by human monocyte-derived macrophages is mediated by the mannose receptor and by the low-density lipoprotein receptor-related protein. Blood 1995; 86: 3421-7.
68. Melchor JP, Strickland S. Tissue plasminogen activator in central nervous system physiology and pathology. Thromb Haemost 2005; 93: 655-60.
69. Jacobsen JS, Comery TA, Martone RL, Elokdah H, Crandall DL, Oganesian A, Martone RL, Elokdah H, Crandall DL, Oganesian A, Aschmies S, Kirksey Y, Gonzales C, Xu J, Zhou H, Atchison K, Wagner E, Zaleska MM, Das I, Arias RL, et al. Enhanced clearance of Abeta in brain by sustaining the plasmin proteolysis cascade. Proc Natl Acad Sci U S A 2008; 105: 8754-9.
70. Su EJ, Fredriksson L, Geyer M, Folestad E, Cale J, Andrae J, Gao Y, Pietras K, Mann K, Yepes M, Strickland DK, Betsholtz C, Eriksson U, Lawrence DA. Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. Nat Med 2008; 14: 731-7.
71. Pawlak R, Melchor JP, Matys T, Skrzypiec AE, Strickland S. Ethanol-withdrawal seizures are controlled by tissue plasminogen activator via modulation of NR2B-containing NMDA receptors. Proc Natl Acad Sci U S A 2005; 102: 443-8.
72. Lijnen HR, Van Hoef B, Nelles L, Collen D. Plasminogen activation with single-chain urokinase-type plasminogen activator (scu-PA). Studies with active site mutagenized plasminogen (Ser740-Ala) and plasmin-resistant scu-PA (Lys158-Glu). J Biol Chem 1990; 265: 5232-6.
73. Gurewich V, Pannell R, Louie S, Kelley P, Suddith RL, Greenlee R. Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase (pro-urokinase). A study in vitro and in two animal species. J Clin Invest 1984; 73: 1731-9.
74. Fleury V, Lijnen HR, Angles-Cano E. Mechanism of the enhanced intrinsic activity of single-chain urokinase-type plasminogen activator during ongoing fibrinolysis. J Biol Chem 1993; 268: 18554-9.
75. Ellis V, Dano K. Potentiation of plasminogen activation by an anti-urokinase monoclonal antibody due to ternary complex formation. A mechanistic model for receptor-mediated plasminogen activation. J Biol Chem 1993; 268: 4806-13.
76. Prager GW, Breuss JM, Steurer S, Mihaly J, Binder BR. Vascular endothelial growth factor (VEGF) induces rapid prourokinase (pro-uPA) activation on the surface of endothelial cells. Blood 2004; 103: 955-62.
77. Kilpatrick LM, Harris RL, Owen KA, Bass R, Ghorayeb C, Bar-Or A, Ellis V. Initiation of plasminogen activation on the surface of monocytes expressing the type II transmembrane serine protease matriptase. Blood 2006; 108: 2616-23.
78. Okumura Y, Hayama M, Takahashi E, Fujiuchi M, Shimabukuro A, Yano M, Kido H. Serase-1B, a new splice variant of polyserase-1/TMPRSS9, activates urokinase-type plasminogen activator and the proteolytic activation is negatively regulated by glycosaminoglycans. Biochem J 2006; 400: 551-61.
79. Moran P, Li W, Fan B, Vij R, Eigenbrot C, Kirchhofer D. Pro-urokinase-type plasminogen activator is a substrate for hepsin. J Biol Chem 2006; 281: 30439-46.
80. Lee SW, Ellis V, Dichek DA. Characterization of plasminogen activation by glycosylphosphatidylinositol-anchored urokinase. J Biol Chem 1994; 269: 2411-8.
81. Tang CH, Wei Y. The urokinase receptor and integrins in cancer progression. Cell Mol Life Sci 2008; 65: 1916-32.
82. Binder BR, Mihaly J, Prager GW. uPAR-uPA-PAI-1 interactions and signaling: A vascular biologist's view. Thromb Haemost 2007; 97: 336-42.
83. Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987; 69: 381-7.
84. Brogren H, Karlsson L, Andersson M, Wang L, Erlinge D, Jern S. Platelets synthesize large amounts of active plasminogen activator inhibitor 1. Blood 2004; 104: 3943-8.
85. Kruithof EK. Plasminogen activator inhibitors - a review. Enzyme 1988; 40: 113-21.
86. Madison EL, Goldsmith EJ, Gerard RD, Gething MJ, Sambrook JF. Serpin-resistant mutants of human tissue-type plasminogen activator. Nature 1989; 339: 721-4.
87. Adams DS, Griffin LA, Nachajko WR, Reddy VB, Wei CM. A synthetic DNA encoding a modified human urokinase resistant to inhibition by serum plasminogen activator inhibitor. J Biol Chem 1991; 266: 8476-82.
88. Mottonen J, Strand A, Symersky J, Sweet RM, Danley DE, Geoghegan KF, Gerard RD, Goldsmith EJ. Structural basis of latency in plasminogen activator inhibitor-1. Nature 1992; 355: 270-3.
89. Declerck PJ, De Mol M, Vaughan DE, Collen D. Identification of a conformationally distinct form of plasminogen activator inhibitor-1, acting as a noninhibitory substrate for tissue-type plasminogen activator. J Biol Chem 1992; 267: 11693-6.
90. De Taeye B, Compernolle G, Dewilde M, Biesemans W, Declerck PJ. Immobilization of the distal hinge in the labile serpin plasminogen activator inhibitor 1: Identification of a transition state with distinct conformational and functional properties. J Biol Chem 2003; 278: 23899-905.
91. Komissarov AA, Zhou A, Declerck PJ. Modulation of serpin reaction through stabilization of transient intermediate by ligands bound to alpha-helix F. J Biol Chem 2007; 282: 26306-15.
92. Medcalf RL, Stasinopoulos SJ. The undecided serpin. The ins and outs of plasminogen activator inhibitor type 2. FEBS J 2005; 272: 4858-67.
93. Yepes M, Lawrence DA. Tissue-type plasminogen activator and neuroserpin: a well-balanced act in the nervous system? Trends Cardiovasc Med 2004; 14: 173-80.
94. Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 1995; 270: 14477-84.
95. Nesheim M, Bajzar L. The discovery of TAFI. J Thromb Haemost 2005; 3: 2139-46.
96. Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 1996; 271: 16603-8.
97. Marx PF, Dawson PE, Bouma BN, Meijers JC. Plasmin-mediated activation and inactivation of thrombin-activatable fibrinolysis inhibitor. Biochemistry 2002; 41: 6688-96.
98. Wang W, Hendriks DF, Scharpe SS. Carboxypeptidase U, a plasma carboxypeptidase with high affinity for plasminogen. J Biol Chem 1994; 269: 15937-44.
99. Bertina RM, van Tilburg NH, Haverkate F, Bouma BN, von demBorne PA, Meijers JC, Campbell W, Eaton D, Hendriks DF, Willemse JL. Discovery of thrombin activatable fibrinolysis inhibitor (TAFI). J Thromb Haemost 2006; 4: 256-7.
100. Campbell W, Okada H. An arginine specific carboxypeptidase generated in blood during coagulation or inflammation which is unrelated to carboxypeptidase N or its subunits. Biochem Biophys Res Commun 1989; 162: 933-9.
101. Schneider M, Boffa M, Stewart R, Rahman M, Koschinsky M, Nesheim M. Two naturally occurring variants of TAFI (Thr-325 and Ile-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme. J Biol Chem 2002; 277: 1021-30.
102. Swaisgood CM, Schmitt D, Eaton D, Plow EF. In vivo regulation of plasminogen function by plasma carboxypeptidase B. J Clin Invest 2002; 110: 1275-82.
103. Guimaraes AH, Laurens N, Weijers EM, Koolwijk P, van Hinsbergh VW, Rijken DC. TAFI and pancreatic carboxypeptidase B modulate in vitro capillary tube formation by human microvascular endothelial cells. Arterioscler Thromb Vasc Biol 2007; 27: 2157-62.
104. Wiman B, Collen D. On the kinetics of the reaction between human antiplasmin and plasmin. Eur J Biochem 1978; 84: 573-8.
105. Rijken DC, Groeneveld E, Kluft C, Nieuwenhuis HK. Alpha 2-antiplasmin Enschede is not an inhibitor, but a substrate, of plasmin. Biochem J 1988; 255: 609-15.
106. Holmes WE, Lijnen HR, Nelles L, Kluft C, Nieuwenhuis HK, Rijken DC, Collen D. Alpha 2-antiplasmin Enschede: Alanine insertion and abolition of plasmin inhibitory activity. Science 1987; 238: 209-11.